Skip to content
No results
  • About Us
  • Contact Us
  • Disclaimer
  • Event Venues
  • Events and Conferences
  • Home
  • Organizer Dashboard
  • Organizer Dashboard
  • Privacy Policy
  • Submit Organizer Form
  • Submit Organizer Form
  • Submit Venue Form
  • Submit Venue Form
  • Subscribe
  • Terms and Conditions
  • Venue Dashboard
  • Venue Dashboard
  • About Us
  • Contact Us
The Pharma Data
Bio Expo
Champignondagen
  • News
  • Press Releases
  • Research
  • Business
  • Regulatory
  • Events and Conferences
The Pharma Data
Azafaros
  • ResearchNews

Azafaros Raises €132M in Series B to Advance Phase 3 LSD Therapies

  • The Pharma Data
  • May 13, 2025

Azafaros Raises €132M in Series B to Advance Phase 3 LSD Therapies Azafaros, a clinical-stage biotechnology company with a specialized focus on rare lysosomal storage disorders (LSDs), announced the successful…

Read MoreAzafaros Raises €132M in Series B to Advance Phase 3 LSD Therapies
InnoCare
  • News

InnoCare’s Mesutoclax Granted Breakthrough Therapy Designation by China’s NMPA

  • The Pharma Data
  • May 12, 2025

InnoCare’s Mesutoclax Granted Breakthrough Therapy Designation by China’s NMPA In a landmark development for China’s oncology therapeutics landscape, InnoCare Pharma Limited (HKEX: 09969; SSE: 688428), a biopharmaceutical company recognized for…

Read MoreInnoCare’s Mesutoclax Granted Breakthrough Therapy Designation by China’s NMPA
  • NewsPress Releases

Hansoh Pharma’s Ameile Approved for Fourth Use in EGFR+ NSCLC Adjuvant Therapy

  • The Pharma Data
  • May 10, 2025

Hansoh Pharma’s Ameile Gains Approval for New Indication in Early-Stage EGFR-Mutant NSCLC Hansoh Pharmaceutical Group Co., Ltd (03692.HK), hereafter referred to as Hansoh Pharma, announced that its innovative product Ameile…

Read MoreHansoh Pharma’s Ameile Approved for Fourth Use in EGFR+ NSCLC Adjuvant Therapy
  • NewsPress Releases

Icotrokinra Shows Strong Results in Hard-to-Treat Scalp and Genital Psoriasis

  • The Pharma Data
  • May 10, 2025

Johnson & Johnson (NYSE: JNJ) today announced promising new results from the Phase 3 ICONIC-TOTAL study evaluating icotrokinra (JNJ-2113), a first-in-class investigational targeted oral peptide designed to selectively block the…

Read MoreIcotrokinra Shows Strong Results in Hard-to-Treat Scalp and Genital Psoriasis
  • BusinessPress Releases

Lilly to Invest $250M in Purdue Partnership for Pharma Innovation

  • The Pharma Data
  • May 10, 2025

Eli Lilly and Purdue University Announce Landmark $250 Million Research Collaboration Eli Lilly and Company (NYSE: LLY) and Purdue University today unveiled a major expansion of their long-standing partnership, with…

Read MoreLilly to Invest $250M in Purdue Partnership for Pharma Innovation
  • ResearchPress Releases

Viatris Reports Positive Phase 3 Results for XULANE LO™ Low-Dose Birth Control Patch

  • The Pharma Data
  • May 9, 2025

A global healthcare company today announced positive top-line results from its Phase 3 clinical trial (NCT05139121) evaluating the contraceptive efficacy and safety of XULANE LO, an investigational low-dose weekly transdermal…

Read MoreViatris Reports Positive Phase 3 Results for XULANE LO™ Low-Dose Birth Control Patch
Lupin
  • Regulatory

Lupin Secures FDA Nod for 600 mg Raltegravir Tablets USP

  • The Pharma Data
  • May 9, 2025

Global pharmaceutical major Lupin Limited announced today that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application (ANDA) for…

Read MoreLupin Secures FDA Nod for 600 mg Raltegravir Tablets USP
  • ResearchPress Releases

Imfinzi Shows Significant Disease-Free Survival Benefit in High-Risk NMIBC: POTOMAC Phase III Trial

  • The Pharma Data
  • May 9, 2025

AstraZeneca announced promising top-line results from its Phase III POTOMAC trial, showing that one year of treatment with Imfinzi (durvalumab) combined with standard-of-care Bacillus Calmette-Guérin (BCG) induction and maintenance therapy…

Read MoreImfinzi Shows Significant Disease-Free Survival Benefit in High-Risk NMIBC: POTOMAC Phase III Trial
  • Press Releases

Shionogi, Partners Join to Boost Antimicrobial Stewardship in Kenya

  • The Pharma Data
  • May 9, 2025

Shionogi Forms Comprehensive Partnership to Strengthen Antimicrobial Stewardship in Kenya Shionogi & Co., Ltd. (Head Office: Chuo-ku, Osaka; “Shionogi”) is pleased to announce that it has signed a comprehensive partnership…

Read MoreShionogi, Partners Join to Boost Antimicrobial Stewardship in Kenya
  • ResearchPress Releases

GLISTEN Phase III: Linerixibat Significantly Eases Itch in PBC

  • The Pharma Data
  • May 9, 2025

GSK Reports Positive Phase III Results for Linerixibat in Treating Itch Associated with PBC GSK plc (LSE/NYSE: GSK) today announced positive results from its GLISTEN phase III trial evaluating linerixibat,…

Read MoreGLISTEN Phase III: Linerixibat Significantly Eases Itch in PBC
  • Business

Merck and Kansas Announce $895M Investment in De Soto Facilities

  • The Pharma Data
  • May 9, 2025

Merck Animal Health and State of Kansas Announce $895 Million Investment in De Soto Manufacturing and R&D Facilities Merck Animal Health launches its largest economic development project to date Rahway,…

Read MoreMerck and Kansas Announce $895M Investment in De Soto Facilities
  • News

Johnson & Johnson Increases Global Efforts to Champion Nurses

  • The Pharma Data
  • May 9, 2025

Johnson & Johnson Expands Global Commitment to Strengthen Nursing Workforce and Improve Healthcare Access Johnson & Johnson today announced the expansion of its efforts to champion the nursing workforce and…

Read MoreJohnson & Johnson Increases Global Efforts to Champion Nurses
PrevNext
UK Biotech Day
Global Clinical
Global Clinical Trial Supply Forum 2026 I Frankfurt, Germany

About

The Pharma Data is an Information-Centric Website focused mainly on the Pharmaceutical Industry Online It is a B2B Platform mainly focused on the latest Pharmaceutical News, Press releases, Industry-related updates, Events, and Conferences. With The Pharma Data, you can get all the information that happening in the Pharmaceutical industry.

Advertise With Us: marketing@thepharmadata.com

Latest Posts

  • Curi Bio and Battelle Partner to Advance Neuromuscular Pharmacology Innovations
  • ImmunityBio Secures Macau Approval for ANKTIVA® to Treat BCG-Unresponsive NMIBC with CIS With or Without Papillary Tumors
  • KalVista to Showcase New EKTERLY® Data at 2026 Global Angioedema Conference
  • About Us
  • Disclaimer
  • Privacy Policy
  • Terms and Conditions
  • Contact Us

Copyright © 2026 | The Pharma Data | Marnet Technologies Pvt Ltd | All Rights Reserved.